NCT02875223 2025-04-20
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
Phase 1 Terminated
Clinical Trials
5 trialsNCT04350463 2025-01-22
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Celgene
Phase 2 Completed
NCT03850067 2024-08-26
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT04628988 2023-09-13
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
Celgene
Phase 1 Completed
NCT04748848 2023-03-02
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
Celgene
Phase 1 Terminated